Actively Recruiting
Cardiac RadiothErapy for VEntricular Tachycardia II
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2026-04-29
50
Participants Needed
1
Research Sites
517 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Steoreotactic therapy radioablation has become a standard of care option for patients with therapy-refractory ventricular tachycardia, yet long-term outcome is lacking. The objective of this study is to evaluate the long-term outcomes, both efficacy and safety, after STAR in patients with therapy-refractory ventricular tachycardia.
CONDITIONS
Official Title
Cardiac RadiothErapy for VEntricular Tachycardia II
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eligible for STAR for therapy-refractory ventricular tachycardia based on a multidisciplinary discussion
- Ability to give written informed consent and willingness to return for follow-up
You will not qualify if you...
- Contraindications for STAR, including pregnancy or breastfeeding
- Previous radiotherapy with cardiac involvement
- Life expectancy less than 6 months in the absence of ventricular tachycardia
- Any condition deemed a contraindication by the investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UZ Leuven
Leuven, Belgium, 3000
Actively Recruiting
Research Team
B
Bert Vandenberk, MD PhD
CONTACT
P
Patrick Berkovic, MD PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here